GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/IBD/Diagnostic performance of intestinal ultrasound compared with CT enterography in Crohn’s disease: single-center experience

Diagnostic performance of intestinal ultrasound compared with CT enterography in Crohn’s disease: single-center experience

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated December 1, 2025

Quick Answer

The study conducted a retrospective single-center analysis to evaluate the diagnostic performance of transabdominal bowel ultrasonography (TBUS) compared with computed tomography enterography (CTE) in identifying intestinal lesions and complications in patients with Crohn’s disease (CD). Crohn’s disease is a chronic inflammatory condition that can affect any part of the gastrointestinal tract and is often associated with complications such as intestinal wall thickening, stenosis, fistulas, and abdominal abscesses.


The study conducted a retrospective single-center analysis to evaluate the diagnostic performance of transabdominal bowel ultrasonography (TBUS) compared with computed tomography enterography (CTE) in identifying intestinal lesions and complications in patients with Crohn’s disease (CD). Crohn’s disease is a chronic inflammatory condition that can affect any part of the gastrointestinal tract and is often associated with complications such as intestinal wall thickening, stenosis, fistulas, and abdominal abscesses. Accurate imaging is critical for diagnosis, monitoring, and long-term follow-up in these patients.

### Key Findings:

1. **Diagnostic Accuracy of TBUS vs. CTE**:

  • TBUS demonstrated comparable diagnostic accuracy to CTE for detecting diseased bowel segments, intestinal wall abnormalities, and complications such as stenosis, fistulas, and abdominal abscesses.
  • TBUS effectively visualized bowel wall thickness, layered structure, vascular changes, and extraintestinal complications.
  • Diagnostic interpretations of TBUS showed strong consistency between different observers, indicating its reliability.

2. **Postoperative Assessment**:

  • TBUS remained effective in patients who had undergone prior intestinal surgery, highlighting its utility in postoperative follow-up.

3. **Advantages of TBUS**:

  • **Non-invasive**: TBUS does not require radiation exposure, making it safer than CTE, particularly for long-term disease monitoring.
  • **Repeatable**: TBUS can be performed frequently without concerns about radiation or invasive procedures.
  • **Practical for Long-Term Monitoring**: TBUS is well-suited for ongoing assessment and follow-up, as it can detect disease progression and complications over time.
  • **Extraintestinal Complications**: TBUS showed strengths in identifying complications outside the intestine, which may guide clinical decision-making.

4. **Clinical Utility**:

  • TBUS proved to be a valuable imaging tool for routine practice and long-term disease management in Crohn’s disease patients.
  • Its ability to provide detailed imaging without the risks associated with CTE makes it an attractive option for clinicians.

### Conclusion:

The study concludes that transabdominal bowel ultrasonography is a highly useful diagnostic tool for Crohn’s disease, offering performance comparable to CT enterography while providing significant advantages in safety, flexibility, and practicality. TBUS is especially beneficial for long-term monitoring, postoperative follow-up, and identifying extraintestinal complications, making it a preferred imaging modality in routine clinical practice for Crohn’s disease management.

Related Q&A

IBD Across Ethnicities: Gastroenterology | July 2026

Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...

Moving Beyond the "Wait to Fail" Strategy in ASUC: FG | 2026

Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...

FMT in Ulcerative Colitis: JGH | July 2026

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...

Engineering Immune Cell Therapies for IBD: Nat Re Gastroe & Hepato | June 2026

Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...

Real-World IBD Patients Rarely Meet Clinical Trial Criteria: AJG | June 2026

Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...

Mirikizumab in Ulcerative Colitis: JCC | June 2026

Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer